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ABSTRACT
Objective: Pathologic ribonuclease H1 (RNase H1) causes aberrant mitochondrial DNA (mtDNA)
segregation and is associated with multiple mtDNA deletions. We aimed to determine the preva-
lence of RNase H1 gene (RNASEH1) mutations among patients with mitochondrial disease and
establish clinically meaningful genotype-phenotype correlations.
Methods: RNASEH1 was analyzed in patients with (1) multiple deletions/depletion of muscle
mtDNA and (2) mendelian progressive external ophthalmoplegia (PEO) with neuropathologic evi-
dence of mitochondrial dysfunction, but no detectable multiple deletions/depletion of muscle
mtDNA. Clinicopathologic and molecular evaluation of the newly identified and previously re-
ported patients harboring RNASEH1 mutations was subsequently undertaken.
Results: Pathogenic c.424G.A p.Val142Ile RNASEH1 mutations were detected in 3 pedigrees
among the 74 probands screened. Given that all 3 families had Indian ancestry, RNASEH1
genetic analysis was undertaken in 50 additional Indian probands with variable clinical presenta-
tions associated with multiple mtDNA deletions, but no further RNASEH1 mutations were con-
firmed. RNASEH1-related mitochondrial disease was characterized by PEO (100%), cerebellar
ataxia (57%), and dysphagia (50%). The ataxia neuropathy spectrum phenotype was observed in
1 patient. Although the c.424G.A p.Val142Ile mutation underpins all reported RNASEH1-
related mitochondrial disease, haplotype analysis suggested an independent origin, rather than
a founder event, for the variant in our families.
Conclusions: In our cohort, RNASEH1 mutations represent the fourth most common cause of
adult mendelian PEO associated with multiple mtDNA deletions, following mutations in POLG,
RRM2B, and TWNK. RNASEH1 genetic analysis should also be considered in all patients with
POLG-negative ataxia neuropathy spectrum. The pathophysiologic mechanisms by which the
c.424G.A p.Val142Ile mutation impairs human RNase H1 warrant further investigation.
Neurol Genet 2017;3:e149; doi: 10.1212/NXG.0000000000000149
GLOSSARY
COX 5 cytochrome c oxidase; IBD 5 identity by descent; mtDNA 5 mitochondrial DNA; NCS 5 nerve conduction studies;
PCA 5 principal component analysis; PEO 5 progressive external ophthalmoplegia; RNase H1 5 ribonuclease H1; RRF 5
ragged red fiber.
Mitochondrial diseases are commonly inherited disorders caused by mutations in nuclear
and mitochondrial DNA (mtDNA). Dysfunction in a subset of nuclear genes involved with
mtDNA maintenance results in the secondary accumulation of multiple deletions and/or
depletion of muscle mtDNA.1 The clinical spectrum of this group of disorders is broad,
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ranging from severe infantile hepatocerebral
syndromes to benign, late-onset progressive
external ophthalmoplegia (PEO). Mutations
in the mtDNA maintenance gene RNASEH1,
encoding ribonuclease H1 (RNase H1), have
recently been linked to adult mitochondrial
disease presenting with CNS and neuromuscu-
lar involvement.2 RNase H1 degrades RNA
hybridized to DNA,3 and knockout mice
suffer embryonic lethality owing to mtDNA
depletion,4 attributable to persistent mtDNA
RNA/DNA hybrids.5 However, humans with
RNASEH1 mutations develop a relatively
mild clinical syndrome, comprising adult-
onset PEO associated with multiple mtDNA
deletions secondary to the impaired physical
segregation of mtDNA molecules.6 The prev-
alence and clinical spectrum of RNASEH1-
related mitochondrial disease is currently
unknown.
We screened 74 unrelated probands with
genetically undetermined mitochondrial
disease for RNASEH1 mutations. The pre-
viously reported pathogenic missense transi-
tion c.424G.A p.Val142Ile was detected in
3 families with Indian ancestry: homozygous
mutations were confirmed in 2 pedigrees
and compound heterozygous mutations
in combination with a novel c.442T.C
p.Cys148Arg variant in a third. Detailed
clinicopathologic and molecular profiling of
these newly identified families harboring
RNASEH1 mutations, and evaluation of all
previously reported cases, was subsequently
undertaken to determine the phenotypic spec-
trum of RNASEH1-mediated mitochondrial
disease and establish clinically meaningful
genotype-phenotype correlations. Finally,
the ancestral origins of the “common”
RNASEH1 c.424G.A p.Val142Ile mutation
were investigated.
METHODS Participants. Patients referred to the London
and Oxford NHS England nationally commissioned service for
mitochondrial diseases were recruited to the study according to
the following criteria: (1) confirmed multiple deletions/depletion
of muscle mtDNA and (2) mendelian PEO with pathologic evi-
dence of mitochondrial dysfunction, including ragged red fibers
(RRFs) and/or cytochrome c oxidase (COX)-negative muscle fi-
bers, without detectable multiple deletions or depletion of muscle
mtDNA. RNASEH1 genetic analysis was also undertaken in
a cohort of Indian patients with evidence of multiple mtDNA
deletions detectable in muscle.
Genetic studies. Whole-exome and Sanger sequencing was used
to analyze the 8 coding exons and intron-exon boundaries of
RNASEH1 (primer sequences available on request).
Clinicopathologic and molecular evaluation of patients.
Patients harboring RNASEH1 mutations were assessed clinically
by the authors. Medical records and muscle tissue histopathologic
and electron microscopy findings were reviewed. Real-time
quantitative PCR of DNA extracted from muscle was under-
taken in all patients harboring RNASEH1mutations and multiple
mtDNA deletions to exclude coexisting mtDNA depletion.
Previously published RNASEH1 variants (pathogenic and of
unknown significance) were evaluated2,7 and clinicopathologic
and genotypic data extracted and combined with the London-
Oxford cohort to accurately define the clinical genetic spectrum
of all known RNASEH1-mediated mitochondrial disease.
Principal component analysis, identity by descent, and
haplotyping. Principal component analysis (PCA), using GCTA
software (version 1.26.0), was performed relative to the HapMap
project populations (CEU, JPT, and YRI) to study the geograph-
ical origin of 2 Indian families where exome-sequencing data were
available (families A and B). Identity by descent (IBD) analysis
was utilized in plink software (v1.90 b1g) to explore the possi-
bility of a common lineage for the pedigrees. Haplotyping was
adopted to investigate the possibility of a common origin for the
c.424G.A p.Val142Ile mutation. Six single nucleotide variants
extracted from available exome data were used to construct
haplotypes around the mutation site, and Sanger sequencing of
the variants in affected individuals from the London-Oxford
cohort and in 2 previously reported families was undertaken.6
Haplotypes were phased around homozygous variant sites only,
given parental samples were unavailable.
Standard protocol approvals, registrations, and patient
consents. The study was approved and performed under the eth-
ical guidelines issued by our institutions for clinical studies, with
written informed consent obtained from all participants for
genetic studies.
RESULTS RNASEH1 sequence data analysis. Seventy-
four unrelated probands were recruited from the
London and Oxford NHS England nationally com-
missioned service for mitochondrial diseases and
categorized as follows: multiple deletions (n 5 33)
and depletion (n 5 21) of muscle mtDNA and
mendelian PEO with neuropathologic evidence
of mitochondrial dysfunction, but no detectable
multiple deletions/depletion of muscle mtDNA
(n 5 20). Homozygous RNASEH1 c.424G.A
p.Val142Ile mutations were identified in 2,
apparently unrelated, nonconsanguineous families
(family A: A-III.8, A-III.9, A-III.10, and A-III.11;
and family B: B-II.1 and B-II.8), and a third singleton
case (family C: C-II.1) was compound heterozygous
with the novel missense mutation c.442T.C
p.Cys148Arg (figure 1A). Parental segregation was
confirmed. All 3 families had Indian ancestry.
Affected individuals harbored multiple deletions of
muscle mtDNA. Fifty additional unrelated Indian
probands with multiple deletions of muscle mtDNA
deletions were screened for RNASEH1 mutations
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(see table e-1 at Neurology.org/ng, for clinicopatho-
logic spectrum), but no known or novel RNASEH1
variants were detected.
Clinicopathologic and molecular features in RNASEH1
mutations. Mean age of symptom onset in the
London-Oxford cohort was 29 years (range, 13–36
years). All patients presented with either ptosis or
imbalance. The clinical phenotype was characterized
by PEO, proximal muscle weakness, and cerebellar
ataxia. One patient had a sensory ataxic neuropathy,
with nerve conduction studies (NCS) and EMG
indicative of a nonlength-dependent, predominantly
sensory, axonal neuropathy. Brain MRI demon-
strated moderate generalized parenchymal volume
loss (n 5 2). Histopathologic examination of muscle
revealed RRFs and COX-negative fibers in all cases
examined, while ultrastructural examination showed
increased and abnormal mitochondria, many with
paracrystalline inclusions (figure 1, B and C). There
was no evidence of a coexisting reduction in muscle
mtDNA copy number (B-II.8 and C-II.1).
Three families (6 affected individuals) with con-
firmed RNASEH1 mutations have previously been
reported.2 An additional case was identified from var-
iants of unknown significance published in exome-
sequencing studies.7 These data were combined with
the London-Oxford cohort and confirmed that PEO
was a universal feature in patients with RNASEH1-
related mitochondrial disease and that a substantial
proportion of patients (57%) exhibited cerebellar dys-
function. Additional clinical features (summarized in
table 1) included dysphagia (50%), proximal muscle
weakness (36%), peripheral neuropathy (36%), and
pyramidal signs (14%). NCS and EMG were consis-
tent with involvement of motor and/or sensory nerve
fibers with demyelinating, axonal, or ganglionic fea-
tures. RRFs and/or COX-deficient fibers and multi-
ple mtDNA deletions were reported in all cases when
muscle tissue was available.
The c.424G.A p.Val142Ile mutation was de-
tected in all 7 families (both newly reported and pre-
viously published). Three were homozygous and 4
were compound heterozygous with the following mu-
tations: c.442T.C p.Cys148Arg (n5 2), c.469C.T
p.Arg157*, and c.554C.T p.Ala185Val.
PCA, IBD, and haplotyping. PCA revealed that fami-
lies A and B clustered to the same ethnic group
(figure 2A, top panel), while IBD analysis implied
a distant relationship to approximately second
cousins (mean PI_HAT 0.049 6 0.013). Haplo-
typing of families A and B suggested one shared
founder haplotype of 3.67 Mb which was also pres-
ent in family C. However, given that the
c.424G.A p.Val142Ile variant was heterozygous,
it was not possible to decipher whether this repre-
sented a population-specific or an ancestral muta-
tion (figure 2A, bottom panel). Analysis of the same
haplotype marker set in 2 previously reported pedigrees
Figure 1 Pedigrees and histopathologic findings of patients harboring RNASEH1 c.424G>A p.Val142Ile mutations
(A) Pedigrees of families harboring RNASEH1 mutations. Filled blue symbols represent affected individuals. Arrows indicate probands. Long range PCR
(LPCR) and Southern blot (SB) demonstrate multiple deletions of muscle mitochondrial DNA (B-II.8) in patient (P) when compared with control muscle (C). (B)
Muscle biopsy histology (A-III.8) demonstrating ragged red fibers (modified Gomori trichrome, GT), ragged blue fibers (succinate dehydrogenase, SDH), and
several muscle fibers deficient in cytochrome c oxidase (COX), arrows. Scale bar represents 50 mm in GT and 200 mm in SDH and COX. (C) Ultrastructural
examination (A-III.8) showing increased numbers of mitochondria, many of which are structurally abnormal, including the presence of paracrystalline
inclusions, arrows. Scale bar represents 1 mm.
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Table 1 Clinicopathologic, biochemical, and genetic features of newly reported and previously published adults with RNASEH1-related mitochondrial disease
Patient Clinical features
Age at
onset, y Brain CT/MRI NCS/EMG
Skeletal muscle
histochemistry RCEA
Multiple
mtDNA
deletions
RNASEH1 cDNA and amino
acid change
A-III.8 PEO, ptosis, facial weakness, proximal muscle
weakness
33 Normal Myopathy RRFs, COX-deficient
fibers
ND Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
A-III.9 PEO, ptosis 32 ND ND RRFs ND ND c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
A-III.10 PEO, ptosis ND ND ND ND ND ND c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
A-III.11 PEO, ptosis ND ND ND ND ND ND c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
B-II.1 PEO, ptosis, ataxia, facial and proximal muscle
weakness
36 Cerebral/cerebellar atrophy ND SDH-positive/COX-
deficient fibers
ND Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
B-II.8 PEO, ptosis, dysarthria, ataxia, facial and
proximal muscle weakness
33 Cerebral/cerebellar atrophy Sensory . motor neuronopathy
and myopathy
RRFs, SDH-positive/
COX-deficient fibers,
neurogenic changes
Normal Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
C-II.1 PEO, ptosis, proximal muscle weakness, ataxia,
diabetes
13 ND Sensory neuropathy RRFs ND Y c.424G.A p.Val142Ile;
c.442T.C p.Cys148Arg
S12 PEO, ptosis, dysphagia, muscle pain, exercise
intolerance, respiratory and lower limb
weakness, ataxia
20 Cerebellar/brain stem atrophy Mild demyelinating motor
neuropathy and myopathy
RRFs, COX-deficient
fibers
Low I/IV Y c.424G.A p.Val142Ile;
c.469C.T p.Arg157*
S22 PEO, ptosis, limb and axial weakness, head
drop, pyramidal features dysphagia, reduced
visual acuity, cerebellar signs
23 ND Mild neurogenic features RRFs, COX-deficient
fibers
Low I/IV Y c.554C.T p.Ala185Val;
c.424G.A p.Val142Ile
S32 PEO, dysphagia, respiratory impairment ND ND ND ND ND Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
S42 PEO, dysphagia, respiratory impairment ND ND ND ND ND Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
S52 PEO, ptosis, dysphonia, dysphagia, pyramidal
signs, cerebellar signs, cognitive impairment
45 Cerebellar/cortical atrophy,
deep periventricular white
matter hyperintensities
Neurogenic features RRFs, COX-deficient
fibers
ND ND c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
S62 PEO, gait instability, severe dysphagia,
respiratory impairment
40 ND ND RRFs, COX-deficient
fibers
ND Y c.424G.A p.Val142Ile;
c.424G.A p.Val142Ile
10197 Bilateral ptosis, PEO, ataxia, fatigue, dysphagia 44 ND ND RRFs, COX-deficient
fibers
ND ND c.424G.A p.Val142Ile;
c.442T.C p.Cys148Arg
Abbreviations: COX 5 cytochrome c oxidase; mtDNA 5mitochondrial DNA; NCS 5 nerve conduction studies; ND 5 not determined; PEO 5 progressive external ophthalmoplegia; RCEA 5 respiratory chain enzyme
analysis; RRF 5 ragged red fiber; SDH 5 succinate dehydrogenase.
Families A, B, and C reported in the current study; S1–62 and 10197 are previously published patients.
4
N
eurology:G
enetics
with European ancestry (S1 and S3) revealed a differ-
ent haplotype at single nucleotide polymorphism
rs10186193, 74 base pairs away from the c.424G.A
p.Val142Ile mutation. These data are consistent with
an independent origin for the c.424G.A p.Val142Ile
mutation in the patients analyzed.
DISCUSSION Based on data obtained from patients
referred to the London and Oxford NHS England
nationally commissioned service for mitochondrial
diseases, RNASEH1 mutations represent the fourth
most common cause of mendelian PEO associated
with multiple mtDNA deletions in adults (2.7%, 3/
109), following mutations in POLG (24.7%, 27/
109), RRM2B (16.5%, 18/109), and TWNK (also
known as C10orf2, PEO1, or Twinkle, 16.5%, 18/
109). Additional, but less frequent, causes of adult
mendelian PEO associated with multiple mtDNA
deletions in our cohort include SLC25A4 (ANT1),
OPA1, MFN2, TYMP, TK2, and SPG7 (1/109,
0.9%), while AFG3L2, DNA2, MGME1, POLG2,
DGUOK, and MPV17 were not detected.
Two families, in whom affected individuals har-
bored multiple mtDNA deletions, were homozygous
for the previously reported c.424G.A p.Val142Ile
mutation, thus confirming its pathogenicity and the
importance of RNase H1 in mtDNA maintenance. A
third proband was compound heterozygous with
a novel missense mutation c.442T.C p.Cys148Arg
in a highly conserved region of the enzyme, resulting
in a hydrophobic amino acid being replaced by a pos-
itively charged residue within the RNase H1 active
site. This mutation was previously reported as a var-
iant of unknown significance in a patient with
PEO harboring the POLG2 variant c.1105A.G
p.Arg369Gly, which was favored as being causative.7
However, a minor allele frequency of 0.003 suggests
that the POLG2 variant c.1105A.G p.Arg369Gly
is a benign polymorphism and unlikely to be delete-
rious.8 Furthermore, the similarity in clinical pheno-
types and association with identical mutations in our
cohort supports the pathogenic basis of RNASEH1
c.442T.C p.Cys148Arg when a second mutant
allele is present.
Clinically, RNASEH1-linked mitochondrial disease
is relatively homogenous, comprising PEO, cerebellar
ataxia, dysphagia, and proximal muscle weakness. This
could reflect similar structural and functional conse-
quences of the reported RNASEH1mutations. Indeed,
all patients are homozygous or heterozygous for
c.424G.A p.Val142Ile, and remaining variants all
occur within in the same catalytic domain (figure
2B). Additional deleterious mutations associated with
more severe, early-onset clinical phenotypes might
exist. However, we did not identify any cases in our
mtDNA depletion cohort. Furthermore, it is possible
that very detrimental mutations are embryonic lethal
as is seen in knockout mice which are completely
deficient in RNase H1.4 Finally, sensory ataxic neu-
ropathy, previously unreported with RNASEH1 mu-
tations, expands the recognized clinical phenotype to
include ataxia neuropathy spectrum, most commonly
associated with recessive POLG mutations.9
IBD analysis confirmed that families A and B
were distantly related. However, their haplotype
Figure 2 Principal component and haplotype analysis of families harboring
c.424G>A p.Val142Ile variant and schematic illustrating the newly
identified and previously reported RNASEH1 mutations to date
(A) Principal component analysis (top panel). X-axis represents component 1; Y-axis repre-
sents component 2. Families A and B cluster to the same ethnic group. Haplotype analysis
of individuals harboring the RNASEH1 mutation c.424G.A p.Val142Ile (bottom panel). “1”
indicates the presence of the marker, “0” indicates the absence of the marker, and “0/1” is
used when haplotype could not be phased. Haplotypes reported are for A-III.8, B-II.8, C-II.1,
S-1, and S-3. Green 5 c.424G.A mutation; gray 5 markers differing from reference hap-
lotype. Families A and B shared a haplotype of at least 3.57 Mb. However, 2 additional
haplotypes were different, suggesting distant recombination events or that the haplotypes
arose independently. (B) The RNASEH1 gene has 8 exons encoding 4 protein domains as
follows: mitochondrial targeting sequencing domain (M), hybrid-binding domain (HBD), con-
nection domain (CD), and ribonuclease H domain (H-domain). The latter conducts all catalytic
activity. Both herein newly identified and previously reported mutations are illustrated in the
schematic. To date, all affected individuals harbor the “common” c.424G.A p.Val142Ile
mutation either in homozygous or heterozygous states. Brackets 5 number of families with
each mutation. Red 5 newly reported variant.
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differed from 2 previously reported European pedi-
grees.2 These data suggest that the c.424G.A
p.Val142Ile mutation has arisen independently in
the lineages analyzed. European admixing of the
London-Oxford Indian families harboring
c.424G.A p.Val142Ile could account for the lack
of RNASEH1 mutations in the 50 additional Indian
probands screened. Furthermore, the close proximity
of all 3 families to the CEU (European) HapMap pro-
ject populations (figure 2A) suggests that they belong
to the Ancestral North Indian gene pool, which shares
up to 70% genetic affinities with Europeans.10
Our data confirm that RNASEH1 mutations are
an important cause of mitochondrial disease result-
ing from the secondary accumulation of multiple
mtDNA deletions and that the phenotypic spec-
trum in adults is relatively benign. Nevertheless,
RNASEH1 genetic analysis should be considered
in all patients presenting with ataxia neuropathy
spectrum once POLG mutations have been
excluded. Finally, although the commonly occur-
ring c.424G.A p.Val142Ile RNASEH1 variant
could indicate a mutation hotspot within the gene,
it might instead reflect an inability of the mutant
enzyme to bind with a partner protein, thereby
allowing Val142Ile RNase H1 to attack its substrates
indiscriminately.6 As such, loss-of-function mutations
could confer different clinical phenotypes.
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